Primary biliary cirrhosis
Information
- Disease name
- Primary biliary cirrhosis
- Disease ID
- Description
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| TSBP1 | 6 | 32,292,698 | 32,371,879 | 30 |
| HLA-B | 6 | 31,353,875 | 31,367,067 | 16 |
| NFKB1 | 4 | 102,501,359 | 102,617,302 | 14 |
| UBE2D3 | 4 | 102,797,357 | 102,868,896 | 14 |
| HLA-DPA1 | 6 | 33,064,569 | 33,080,710 | 14 |
| STAT4 | 2 | 191,029,576 | 191,151,595 | 10 |
| BTNL2 | 6 | 32,393,339 | 32,407,181 | 10 |
| MICA | 6 | 31,403,595 | 31,415,315 | 10 |
| TAP2 | 6 | 32,825,415 | 32,838,402 | 10 |
| TNFSF8 | 9 | 114,901,145 | 114,930,591 | 10 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02924701 | Active, not recruiting | sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis | September 2016 | September 2031 | |
| NCT04526665 | Active, not recruiting | Phase 3 | Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) | September 24, 2020 | December 1, 2028 |
| NCT01161953 | Active, not recruiting | Genetic Epidemiology of Primary Biliary Cirrhosis (PBC) | March 2002 | December 2050 | |
| NCT00588302 | Completed | Phase 2 | Moexipril for Primary Biliary Cirrhosis | June 2003 | June 2007 |
| NCT00805805 | Completed | Phase 3 | Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis | April 2006 | December 2008 |
| NCT00844402 | Completed | Phase 3 | Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis | January 2006 | November 2007 |
| NCT00943176 | Completed | Phase 1 | Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC) | June 2009 | April 2011 |
| NCT01603199 | Completed | N/A | High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis | September 2011 | June 2016 |
| NCT00490620 | Completed | Phase 2/Phase 3 | Study of Combivir for Patients With Primary Biliary Cirrhosis | January 2004 | April 2007 |
| NCT00575042 | Completed | Phase 2 | Use of Fenofibrate for Primary Biliary Cirrhosis | August 2007 | August 2010 |
| NCT01857284 | Completed | Phase 3 | Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis | September 2009 | January 2013 |
| NCT01865812 | Completed | Phase 2 | Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis | December 3, 2013 | September 12, 2016 |
| NCT01879735 | Completed | Phase 1 | Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT | June 2013 | September 2014 |
| NCT01904058 | Completed | Phase 2 | Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis | August 2013 | April 2015 |
| NCT02026401 | Completed | Phase 2 | Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis | February 2014 | December 2014 |
| NCT02078882 | Completed | Phase 4 | Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis | September 2014 | October 2018 |
| NCT02135536 | Completed | Phase 2 | Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis | May 2014 | February 2016 |
| NCT02376335 | Completed | Phase 2 | B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis | October 2012 | September 2016 |
| NCT02477462 | Completed | Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients | May 2015 | June 6, 2019 | |
| NCT02557360 | Completed | Phase 4 | Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis | November 2015 | March 2017 |
| NCT02659696 | Completed | Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis | September 2015 | March 2018 | |
| NCT02823353 | Completed | Phase 3 | Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis | April 8, 2016 | June 2022 |
| NCT02846896 | Completed | The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland | December 2015 | March 2017 | |
| NCT02955602 | Completed | Phase 2 | Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) | November 28, 2016 | July 8, 2019 |
| NCT02963077 | Completed | Phase 1 | A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 | July 2013 | May 2014 |
| NCT03082937 | Completed | Phase 1 | An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects | January 31, 2017 | March 8, 2017 |
| NCT03112681 | Completed | Phase 2 | Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis | August 18, 2017 | August 7, 2020 |
| NCT03226067 | Completed | Phase 2 | Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. | June 26, 2017 | April 11, 2019 |
| NCT03253276 | Completed | Early Phase 1 | Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT | May 19, 2016 | September 20, 2018 |
| NCT03489889 | Completed | N/A | Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine | December 2016 | June 2018 |
| NCT03590886 | Completed | Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response | August 22, 2018 | February 28, 2019 | |
| NCT03665519 | Completed | N/A | Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis | January 3, 2018 | December 1, 2020 |
| NCT03809559 | Completed | Repeatability and Reproducibility of Quantitative MRCP | July 19, 2018 | March 8, 2019 | |
| NCT03941184 | Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity | January 1, 1995 | November 10, 2020 | |
| NCT04522869 | Completed | Phase 1/Phase 2 | Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia | August 10, 2019 | October 25, 2021 |
| NCT04604652 | Completed | Phase 2 | Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis | May 27, 2021 | May 31, 2022 |
| NCT04791527 | Completed | N/A | Online Wellness Intervention for Primary Biliary Cholangitis (PBC) | February 14, 2021 | December 31, 2023 |
| NCT05374200 | Completed | N/A | Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC) | October 3, 2021 | April 9, 2022 |
| NCT01249092 | Completed | Phase 2 | Pentoxifylline for Primary Biliary Cirrhosis | November 2010 | March 2013 |
| NCT01389973 | Completed | Phase 2 | A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid | September 2011 | June 2013 |
| NCT01473524 | Completed | Phase 3 | Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis | January 2012 | December 17, 2018 |
| NCT01510860 | Completed | Phase 4 | Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis | November 2008 | July 2010 |
| NCT00364819 | Completed | Phase 1/Phase 2 | Initial Study of Rituximab to Treat Primary Biliary Cirrhosis | January 2007 | December 2009 |
| NCT01614405 | Completed | N/A | Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis | June 2012 | August 2015 |
| NCT06061341 | Not yet recruiting | TruGraf Liver Gene Expression Serial Test | April 2024 | December 2026 | |
| NCT01793168 | Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford | July 2010 | December 2100 | |
| NCT03301506 | Recruiting | Phase 3 | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | December 12, 2017 | December 2025 |
| NCT02931513 | Recruiting | sCD163 in PBC Patients - Assessment of Treatment Response | September 2016 | September 2031 | |
| NCT03445585 | Recruiting | Biobank for Cholestatic Liver Diseases. | January 2017 | January 2050 | |
| NCT04514965 | Recruiting | Bezafibrate in Patients With Primary Biliary Cholangitis (PBC) | October 1, 2020 | September 2026 | |
| NCT00746486 | Terminated | Phase 3 | Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC) | February 2009 | October 2019 |
| NCT01430429 | Terminated | Phase 2 | Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody | ||
| NCT04278820 | Unknown status | Phase 2 | A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC) | March 20, 2020 | November 30, 2022 |
| NCT04933292 | Unknown status | Phase 4 | A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome | June 16, 2021 | May 2022 |
| NCT03668145 | Unknown status | N/A | Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis | November 8, 2017 | December 31, 2020 |
| NCT02916290 | Unknown status | Phase 3 | Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis | January 2016 | |
| NCT02916641 | Unknown status | Phase 3 | Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid | January 2016 | |
| NCT01440309 | Unknown status | Phase 1 | Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis | November 2011 | December 2013 |
| NCT02937012 | Unknown status | Phase 3 | Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders | October 2016 | December 2019 |
| NCT03743272 | Unknown status | Repeatability and Reproducibility of Multiparametric MRI | June 3, 2017 | November 1, 2022 | |
| NCT01662973 | Unknown status | Phase 1/Phase 2 | Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis | October 2011 | October 2013 |
| NCT04893993 | Unknown status | Phase 4 | PBC Induced Fatigue Treated With Thiamine | May 12, 2021 | December 2023 |
| NCT02193360 | Unknown status | Phase 1/Phase 2 | Pilot Study of FFP104 Dose Escalation in PBC Subjects | May 2015 | December 2017 |
| NCT03337074 | Unknown status | Paternally Inherited Phenotypes in Cholestasis | February 8, 2017 | April 30, 2020 | |
| NCT04956328 | Unknown status | Phase 3 | Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC) | July 22, 2021 | September 20, 2023 |
| NCT04751188 | Unknown status | Phase 3 | A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis | October 2, 2020 | July 2021 |
| NCT02823366 | Unknown status | Phase 3 | Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid | January 2016 | December 2023 |
| NCT02965911 | Withdrawn | Phase 1/Phase 2 | Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA | January 2016 | September 8, 2021 |
| NCT00393185 | Withdrawn | Phase 1 | Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis | January 2006 | January 2012 |
| NCT02321306 | Withdrawn | Phase 2 | An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis | May 2015 | March 2018 |
| NCT01141296 | Withdrawn | Phase 2 | Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis | April 2011 | |
| NCT00587119 | Withdrawn | N/A | Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis | December 2007 | July 2009 |
- ICD10 preferred id (Insert disease from ICD10)
- D0008854
- ICD10 class code (Insert disease from ICD10)
- K74.3